Crown laboratories commences friendly tender offer for all outstanding common shares of revance therapeutics at $3.10 per share

Board of directors of revance recommend stockholders tender their shares johnson city, tenn. , dec. 12, 2024 /prnewswire/ -- crown laboratories, inc. ("crown"), a privately held, global innovative leader in the skincare industry, today announced that it has commenced a cash tender offer to acquire all outstanding shares of common stock of revance therapeutics, inc., ("revance") (nasdaq: rvnc) at a price of $3.10 per share in cash.
RVNC Ratings Summary
RVNC Quant Ranking